
Emcura Medical Weight Loss Program and Agreement (2025 Update)

What are Semaglutide or Tirzepatide and Why Are They Prescribed for Weight Loss?

Semaglutide (Wegovy®) and Tirzepatide (Zepbound®) are FDA-approved GLP-1 receptor agonists used for weight loss in adults with obesity or overweight and related health conditions. These medications work by slowing stomach emptying, improving insulin use, reducing appetite, and supporting weight loss.

GLP-1 medications may reduce risks of diabetes, high blood pressure, heart disease, and other obesity-related complications. However, weight loss outcomes vary and are not guaranteed.

What GLP-1 Options Are Offered at Emcura Medical? How Are These Medications Used? Important Legal Note (2025):

At Emcura, patients may access:

- Commercial FDA-Approved Options: Wegovy® (semaglutide) and Zepbound® (tirzepatide), ordered directly through the manufacturer.
- Compounded Options: Oral compounded semaglutide or tirzepatide (sometimes combined with vitamin B12 or Niacinamide).
- Compounded GLP-1 medications are not FDA-approved but we use the largest Compounding Pharmacy in the country, who provides stability in strength, absorption, and safety.
- Federal guidance limits compounding to situations where FDA-approved drugs are unavailable, medically unsuitable or customized to a patient's needs.
- Prescribers ordering compounded versions do so to meet specific patient needs; patients must acknowledge this legal and safety difference.
- Long-term safety data for compounded GLP-1s is limited, but the active ingredients are the same.

Patient Initials: _____

What is the Cost Through Emcura?

- Visits: Initial - Billed through insurance when eligible or 75\$ per visit. - Follow-up visits: \$75 self-pay or billed for Medicare or Medicaid.
- Medication costs: depend on manufacturer program (e.g., Wegovy®, Zepbound®) or see our most recent compounding pharmacy pricing through Wellness by Emcura.

Patient Initials: _____

Why Choose Emcura Medical Weight Loss?

Emcura focuses on sustainable weight management, not just quick results. Our approach includes:

- Regular monitoring of weight, body composition, and muscle mass.
- Individualized lifestyle and nutrition guidance.
- Ongoing professional support to reduce the risk of regaining lost weight and will help manage your taper to help keep weight off.

Studies show that patients without ongoing supervision regain weight quickly—even with medication.

Long-term success depends on follow-up, adherence, and lifestyle change.

Patient Initials: _____

Options for Semaglutide or Tirzepatide, Compounded or Commercial

Patients may choose between FDA-approved or compounded formulations, with full understanding of differences in regulation, safety, and liability.

- Commercial injectables are preferred for safety, reliability, and quality assurance.
- Compounded oral options are considered alternative-use therapies and are not equivalent to FDA-approved products.
- Legal actions by manufacturers may affect compounded product availability at any time.

Patient Initials: _____

Monthly Visits for Dose Adjustment

- Monthly visits required during dose titration.
- Every 2 months allowed once a stable dose is reached.
- These visits are essential for safety, effectiveness, and prescription renewal.
- Missed visits may result in denial of medication refills.

Patient Initials: _____

Purchasing Commercial or Compounded Medications

- Commercial prescriptions are placed with the manufacturer, who will bill and ship directly.
- Compounded medications are dispensed through Emcura and we only order through select compounding pharmacies.
- Medication must only be used by the patient, stored properly, and discarded after expiration or 28 days post-first use (for injectables).

Patient Initials: _____

Acknowledgment of Emcura Medical Supervision and Follow-Up

I understand:

- GLP-1 therapy requires ongoing supervision.
- Dose increases may only occur during scheduled follow-ups at the Provider's discretion.
- Skipping follow-ups increases risks of complications and limits treatment eligibility.

Patient Initials: _____

Compliance with Prescribed Dose

- I agree not to exceed prescribed dosing.
- I understand overuse may cause gastroparesis, dehydration, kidney injury, or death.
- I will promptly report difficulties with adherence.

Patient Initials: _____

Injection Timing, Patient Preference, and Side Effect Management

- Injections must be scheduled at least 7 days apart.
- Most side effects occur within 24–72 hours after dosing.
- Patients should choose injection days that minimize lifestyle disruptions.
- Nausea is common and may be managed with hydration (oral or IV). Severe vomiting requires medical evaluation and possible IV hydration.

Patient Initials: _____

Contraindications, Adverse Effects, and Other Considerations

Contraindications:

- Personal/family history of medullary thyroid carcinoma (MTC)
- MEN 2 (Multiple Endocrine Neoplasia syndrome type 2)
- Type 1 diabetes
- History of pancreatitis
- Allergy to GLP-1 medications or ingredients

Known Risks:

- Pancreatitis
- Gallbladder disease
- Kidney injury
- Diabetic retinopathy worsening
- Severe gastrointestinal slowing or obstruction
- Hypoglycemia (if used with other diabetes meds)
- Thyroid tumors (observed in animals)

Common Side Effects:

- Nausea, vomiting, diarrhea, constipation, bloating, heartburn, fatigue, burping.

Long-Term Risks:

- Because these are relatively new medications, unknown long-term complications may occur. I accept this uncertainty.

Pregnancy/Fertility:

- Must stop GLP-1 therapy at least 2 months prior to pregnancy.
- Notify provider immediately if pregnant or planning pregnancy.

Patient Initials: _____

I understand that Weight Loss is Not Guaranteed:

- Medication alone does not guarantee weight loss and results depend on nutrition, physical activity, sleep, stress, genetics, and hormonal balance. Some patients may lose little or no weight despite compliance.

Patient Initials: _____

General Consent and Disclaimer

I understand that:

- All medical treatments carry risks and providers at Emcura cannot guarantee outcomes.
- I have had the opportunity to ask questions and I consent to proceed, knowing there may be both known and unknown complications.

Provider Signature: _____ Date: _____

Patient Signature: _____ Date: _____

2025 Emcura Medical GLP-1 Weight Loss Price List

OFFICIAL WEGOVY or ZEPBOUND

We order Direct from the Manufacturer to Ship to your Home

Medication	Dose	Purchase Price
Wegovy (Semaglutide)	0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2.4 mg	0.25 mg w/ coupon (\$299-350) \$499.00 / month all doses
Zepbound (Tirzepatide)	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	\$350.00 - 2.5 mg only, then \$499.00 / month all doses

COMPOUNDED SEMAGLUTIDE / CYANOCOBALAMIN or TIRZEPATIDE / NIACINAMIDE

Our personalized and customized GLP-1 program. Ordered directly to your home or to clinic.

Medication	Dose	Purchase Price
Semaglutide/ Cyanocobalamine	Stage 1- 0.125 mg – 0.3 mg Stage 2 - 0.35 mg to 0.6 mg	\$195.00 / vial (2.5 mg total)
Semaglutide/ Cyanocobalamine	Stage 3 - 0.7 mg to 1.2 mg Stage 4 - 1.3 mg to 1.7 mg Stage 5 - 1.8 mg to 2.2 mg Stage 6 – 2.3 mg to 2.5 mg	\$ 275.00 / vial (12.5 mg total)
Tirzepatide / Niacinamide	Stage 1- 0.5 mg – 3 mg	\$ 275.00 / vial (20 mg total)
Tirzepatide / Niacinamide	Stage 2 - 4 mg to 6 mg Stage 3 - 7 mg to 9 mg	\$ 350.00 / vial (34 mg total)
Tirzepatide / Niacinamide	Stage 4 - 10 mg to 11 mg Stage 5 - 12 mg to 13 mg Stage 6 - 14 mg to 15 mg	\$ 650.00 / vial (68 mg total)

**Please discard vial 28 days after first
puncture per CDC recommendation*